Crispr Therapeutics AG (CRSP) stock has gained 12.88% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,bullish
Crispr Therapeutics AG has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRSP!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.

InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.

Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CRSP Stock Today?

Crispr Therapeutics AG (CRSP) stock has risen 8.59% while the S&P 500 is unchanged 0% as of 11:17 AM on Wednesday, Aug 19. CRSP is higher by $8.15 from the previous closing price of $94.92 on volume of 1,400,429 shares. Over the past year the S&P 500 has gained 15.68% while CRSP is higher by 112.17%. CRSP earned $0.47 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 221.99.

To screen for more stocks like Crispr Therapeutics AG click here.

More About Crispr Therapeutics AG

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.



Source link